Successful Treatment of EGFR-Mutant Synchronous SCLC and Lung Adenocarcinoma With Osimertinib [0.03%]
奥希替尼成功治疗EGFR突变同步小细胞肺癌和肺腺癌
Ullas Batra,Shrinidhi Nathany,Mansi Sharma et al.
Ullas Batra et al.
Combination of Atezolizumab, Bevacizumab, and Chemotherapy (IMpower 150) in a Patient With NSCLC Having Leptomeningeal Metastases [0.03%]
阿特珠单抗，贝伐单抗和化疗(IMpower 150)联合用于有脑膜转移的非小细胞肺癌患者中的应用
Jordi Remon,María Castro-Henriques,Laura Esteller et al.
Jordi Remon et al.
Reply to Cortellini A [0.03%]
回复Cortellini A
Biagio Ricciuti,Mark M Awad
Biagio Ricciuti
Thirteen-Year Survival in a Patient With Diffuse Bilateral Lepidic-Predominant Adenocarcinoma: A Case Report of Lung Transplantation and Local Salvage [0.03%]
弥漫性双侧以鳞状为主腺癌患者十三年的生存报告：一例肺移植和局部挽救的病例报告
Elizabeth R Zhang-Velten,David E Gerber,Kenneth D Westover
Elizabeth R Zhang-Velten
Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1-Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms [0.03%]
Pegargiminase联合培美曲塞和顺铂用于精氨琥珀酸合成酶1缺陷型间皮瘤患者I期临床试验：安全性，疗效及耐药机制研究
Peter W Szlosarek,Melissa M Phillips,Iuliia Pavlyk et al.
Peter W Szlosarek et al.
Introduction: Pegargiminase (ADI-PEG 20; ADI) degrades arginine and potentiates pemetrexed (Pem) cytotoxicity in argininosuccinate synthetase 1 (ASS1)-deficient malignant pleural mesothelioma (MPM). We conducted a phase 1...
Optimizing Sequential Treatment With EGFR Tyrosine Kinase Inhibitor With a Simulation of the T790M Mutation Rate in EGFR-Mutated Lung Cancer [0.03%]
通过模拟T790M突变率来优化EGFR突变肺癌中酪氨酸激酶抑制剂的序贯治疗方案
Naoki Haratake,Toshihiro Misumi,Takeharu Yamanaka et al.
Naoki Haratake et al.
Introduction: The mutation rate of T790M might change the effective therapeutic sequence of EGFR tyrosine kinase inhibitors (TKIs). This simulation estimates the T790M positivity rate required for first-line first- or sec...
Src-Homology 2 Domain-Containing Phosphatase 2 in Resected EGFR Mutation-Positive Lung Adenocarcinoma [0.03%]
SRC同源2域含磷酸酶2在切除的EGFR突变阳性肺腺癌中的作用
Masaoki Ito,Jordi Codony-Servat,Ana Giménez-Capitán et al.
Masaoki Ito et al.
Introduction: EGFR mutation-positive lung adenocarcinoma (LUAD) displays impaired phosphorylation of ERK and Src-homology 2 domain-containing phosphatase 2 (SHP2) in comparison with EGFR wild-type LUADs. We hypothesize th...
Survival Outcomes of Salvage Therapy for Local and Regionally Recurrent NSCLC [0.03%]
局部和区域复发的非小细胞肺癌再治疗的生存结果
Sara Moore,Bonnie Leung,Jonn Wu et al.
Sara Moore et al.
Introduction: The treatment of locally recurrent NSCLC after initial curative therapy is variable. We sought to perform a real-world analysis of curative and palliative therapeutic strategies used in locally recurrent NSC...
Acquired Exon 14 MET Mutation Associated With Resistance to Alectinib in a Patient With ALK- Rearranged NSCLC [0.03%]
ALK重排的NSCLC患者中与对Alectinib耐药相关的获得性MET 外显子14突变
Catherine Daniel,Celine Callens,Samia Melaabi et al.
Catherine Daniel et al.
Prolonged Central Nervous System Response in a Patient With HER2 Mutant NSCLC Treated With First-Line Poziotinib [0.03%]
使用Poziotinib治疗的HER2突变型NSCLC患者的中枢神经系统长期反应
Nishan Tchekmedyian,Bill Paxton,Francois Lebel et al.
Nishan Tchekmedyian et al.